Lantern Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

Lantern Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.5K	Hold	10,000	–	–	0.04%	183
2026 Q1	$34.9K	Buy	+10,000	New	+$36K	0.02%	173
2025 Q4	–	Sell	-15,000	Closed	-$75.5K	–	164
2025 Q3	$75.5K	Hold	15,000	–	–	0.04%	153
2025 Q2	$51.5K	Buy	+15,000	New	+$37.3K	0.03%	147
2024 Q4	$52.7K	Sell	18,000 -5,300	-23%	-$14.8K	0.03%	134
2024 Q3	$60.6K	Hold	23,300	–	–	0.04%	127
2024 Q2	$69K	Buy	23,300 +750	+3%	+$2.84K	0.05%	128
2024 Q1	$102K	Hold	22,550	–	–	0.07%	126
2023 Q4	$129K	Buy	+22,550	New	+$105K	0.1%	113

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Lantern Wealth Advisors's ABCL Position: Q2 2026 in Review

Lantern Wealth Advisors held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 10,000 shares worth $78.5K. The position accounts for 0.04% of the portfolio, ranked #183.

Lantern Wealth Advisors first reported a position in ABCL in Q4 2023 and has held it in 9 quarters since. The position peaked at $129K in Q4 2023. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Lantern Wealth Advisors held 10,000 shares of AbCellera Biologics worth $78.5K as of Q2 2026.
Lantern Wealth Advisors left its AbCellera Biologics share count unchanged in Q2 2026.
AbCellera Biologics made up 0.04% of Lantern Wealth Advisors's portfolio in Q2 2026, its #183 holding.
Lantern Wealth Advisors first reported a position in AbCellera Biologics in Q4 2023 and has held it in 9 quarters since.
Lantern Wealth Advisors's AbCellera Biologics position peaked at $129K in Q4 2023.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Lantern Wealth Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.